Effect of selected nonsteroidal anti-inflammatory drugs on the viability of canine osteosarcoma cells of the D-17 line: in vitro studies
References
- Abdelrahim M., Baker C.H., Abbruzzese J.L., Safe S.: Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006, 98, 855–868.
- Basha R., Ingersoll S.B., Sankpal U.T., Ahmad S., Baker C.H., Edwards J.R., Holloway R.W., Kaja S., Abdelrahim M.: Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 2011, 122, 163–170.
- Chen W.S., Wei S.J., Liu J.M., Hsiao M., Kou-Lin J., Yang W.K.: Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001, 91, 894–899.
- Choi E.S., Shim J.H., Jung J.Y., Kim H.J., Choi K.H., Shin J.A., Nam J.S., Cho N.P., Cho S.D.: Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer Sci 2011, 102, 742–748.
- Colon J., Basha M.R., Madero-Visbal R., Konduri S., Baker C.H., Herrera L.J., Safe S., Sheikh-Hamad D., Abudayyeh A., Alvarado B., Abdelrahim M.: Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 2011, 29, 41–51.
- Eslin D., Sankpal U.T., Lee C., Sutphin R.M., Maliakal P., Currier E., Sholler G., Khan M., Basha R.: Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma. Mol Carcinog 2013, 52, 377–386.
- Grandemange E., Fournel S., Boisramé B.: Field evaluation of the efficacy of tolfenamic acid administered in one single preoperative injection for the prevention of postoperative pain in the dog. J Vet Pharmacol Ther 2007, 30, 503–507.
- Hillers K.R., Dernell W.S., Lafferty M.H., Withrow S.J., Lana S.E.: Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986–2003). J Am Vet Med Assoc 2005, 226, 1364–1367.
- Khwaja F.S., Quann E.J., Pattabiraman N., Wynne S., Djakiew D.: Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Mol Cancer Ther 2008, 7, 3539–3545.
- McKellar Q.A., Lees P., Gettinby G.: Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol 1994, 253, 191–200.
- Mullins M.N., Lana S.E., Dernell W.S., Ogilvie G.K., Withrow S.J., Ehrhart E.J.: Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med 2004, 18, 859–865.
- Okamoto A., Shirakawa T., Bito T., Shigemura K., Hamada K., Gotoh A., Fujisawa M., Kawabata M.: Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo Urology 2008, 71, 156–160.
- Pang L.Y., Argyle S.A., Kamida A., Morrison K.O., Argyle D.J.: The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro BMC Vet Res 2016, 10, 184.
- Papineni S., Chintharlapalli S., Abdelrahim M., Lee S.O., Burghardt R., Abudayyeh A., Baker C., Herrera L., Safe S.: Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009, 30, 1193–1201.
- Rosenberger J.A., Pablo N.V., Crawford P.C.: Prevalence of and intrinsic risk factors for appendicular osteosarcoma in dogs: 179 cases (1996–2005). J Am Vet Med Assoc 2007, 231, 1076–1080.
- Roze M., Thomas E., Davot J.L.: Tolfenamic acid in the control of ocular inflammation in the dog: pharmacokinetics, and clinical results obtained in an experimental model. J Small Anim Pract 1996, 37, 371–375.
- Ru G., Terracini B., Glickman L.T.: Host related risk factors for canine osteosarcoma. Vet J 1998, 156, 31–39.
- Shigemura K., Shirakawa T., Wada Y., Kamidono S., Fujisawa M., Gotoh A.: Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo Urology 2005, 66, 1239–1244.
- Spodnick G.J., Berg J., Rand W.M., Schelling S.H., Couto G., Harvey H.J., Henderson R.A., MacEwen G., Mauldin N., McCaw D.L.: Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 1992, 200, 995–999.
- Wilson H., Chadalapaka G., Jutooru I., Sheppard S., Pfent C., Safe S.: Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (Sp) transcription factors, and Sp-regulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cells. J Vet Intern Med 2012, 26, 977–986.
- Withrow S.J., Vail M.D.: Withrow and MacEwen’s Small Animal Clinical Oncology, edited by S.J. Withrow, D.M. Vail, W.B. Saunders, St. Louis, 2007, p. 71.
DOI: https://doi.org/10.2478/jvetres-2019-0051 | Journal eISSN: 2450-8608
Language: English
Page range: 399 - 403
Submitted on: Feb 13, 2019
Accepted on: Jul 26, 2019
Published on: Sep 13, 2019
Published by: National Veterinary Research Institute in Pulawy
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2019 Dominik Poradowski, Bożena Obmińska-Mrukowicz, published by National Veterinary Research Institute in Pulawy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.